The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1b study of the novel first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in combination with pembrolizumab in patients with immune checkpoint inhibitor (ICI)-relapsed and refractory solid malignancies and dose escalation update.
 
Carolyn Muller
Research Funding - agenus (Inst); AstraZeneca (Inst); Genmab (Inst); Incyte (Inst); Linnaeus Therapeutics (Inst); Merck (Inst); Roche/Genentech (Inst); TapImmune Inc. (Inst); VBL Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Have a pending patent on the cancer use for R-ketorolac - not yet its own new drug. (Inst)
Other Relationship - Department of Defense; NCI; NCI
 
Marya F. Chaney
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Justine Vanessa Cohen
Honoraria - Genzyme; Regeneron
Consulting or Advisory Role - Bristol-Myers Squibb; Genzyme
 
Tina Garyantes
Employment - Linnaeus Therapeutics
Leadership - Linnaeus Therapeutics
Stock and Other Ownership Interests - Linnaeus Therapeutics (Inst)
Research Funding - Linnaeus Therapeutics
Patents, Royalties, Other Intellectual Property - Linnaeus Therapeutics
Travel, Accommodations, Expenses - Linnaeus Therapeutics
 
Jessica Jiyeong Lin
Honoraria - OncLive; Pfizer
Consulting or Advisory Role - Bayer; Blueprint Medicines; C4 Therapeutics; Elevation Oncology; Genentech; Mirati Therapeutics; Novartis; Nuvalent, Inc.; Turning Point Therapeutics
Research Funding - Bayer (Inst); Elevation Oncology (Inst); Hengrui Therapeutics (Inst); Linnaeus Therapeutics (Inst); Neon Therapeutics (Inst); Novartis (Inst); Nuvalent, Inc. (Inst); Relay Therapeutics (Inst); Roche (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Pfizer
 
Patricia LoRusso
Honoraria - Five Prime Therapeutics
Consulting or Advisory Role - Abbvie; ABL Bio; Agenus; Agios; Astellas Pharma; AstraZeneca; BAKX Therapeutics; Bayer; Black Diamond Therapeutics; Compass Therapeutics; Cybrexa Therapeutics; CytomX Therapeutics; EMD Serono; Five Prime Therapeutics; Genentech; Genmab; GlaxoSmithKline; Halozyme; I-Mab; ImCheck therapeutics; ImmunoMet; IQvia; Kineta; Kyowa Kirin International; Macrogenics; Mekanistic Therapeutics; Molecular Templates; Molecular Templates; Pfizer; QED Therapeutics; Relay Therapeutics; Roche/Genentech; Salarius Pharmaceuticals; Seagen; Shattuck Labs; Silverback Therapeutics; SK Life Sciences; Sotio; ST Cube; Stemline Therapeutics; Takeda; Trial to Reduce IDDM in the Genetically at Risk (TRIGR); TYME; Zentalis
Research Funding - Genentech (Inst)
Travel, Accommodations, Expenses - Genentech
 
Alain C. Mita
Speakers' Bureau - Genentech
 
Monica M. Mita
Research Funding - Seagen (Inst)
 
Christopher Natale
Employment - Linnaeus Therapeutics
Stock and Other Ownership Interests - Linnaeus Therapeutics
Patents, Royalties, Other Intellectual Property - Inventor on Patents held by Linnaeus Therapeutics and the University of Pennsylvania
 
Marlana M. Orloff
Consulting or Advisory Role - IDEAYA Biosciences; Immunocore; TriSalus Life Sciences
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); IDEAYA Biosciences (Inst); IDEAYA Biosciences (Inst); Immunocore (Inst); Linnaeus Therapeutics (Inst); Plexxikon (Inst)
 
Kyriakos P. Papadopoulos
Consulting or Advisory Role - Basilea; Bicycle Therapeutics; Turning Point Therapeutics
Research Funding - 3D Medicines (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Biontech (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); F-star (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Kezar Life Sciences (Inst); Lilly (Inst); Linnaeus Therapeutics (Inst); MabSpace Biosciences (Inst); MedImmune (Inst); Merck (Inst); Mersana (Inst); Mirati Therapeutics (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)
 
Sapna Pradyuman Patel
Honoraria - Delcath Systems; Immunocore; Merck
Consulting or Advisory Role - Castle Biosciences; TriSalus Life Sciences
Research Funding - Bristol-Myers Squibb (Inst); Deciphera (Inst); Foghorn Therapeutics (Inst); InxMed (Inst); Lyvgen Biopharma (Inst); Novartis (Inst); Provectus (Inst); Reata Pharmaceuticals (Inst); Seagen (Inst); Syntrix Biosystems (Inst); TriSalus Life Sciences (Inst)
Travel, Accommodations, Expenses - TriSalus Life Sciences
Other Relationship - Immunocore
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Ellipses Pharma; iOnctura; Kelun Pharmaceuticals/Klus Pharma; Molecular Partners; Peptomyc
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst)
Travel, Accommodations, Expenses - ESMO
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social